Astellas Pharma (OTCMKTS:ALPMY) Stock Rating Lowered by Zacks Research

Astellas Pharma (OTCMKTS:ALPMY) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued on Monday,Zacks.com reports.

Other research analysts have also recently issued reports about the stock. Jefferies Financial Group raised shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 24th. Smbc Nikko Sec. upgraded shares of Astellas Pharma to a “hold” rating in a research report on Monday, February 16th. One research analyst has rated the stock with a Strong Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold”.

Astellas Pharma Stock Down 2.0%

Astellas Pharma stock opened at $13.93 on Monday. The stock has a market cap of $25.21 billion, a P/E ratio of 12.97 and a beta of 0.08. The company has a quick ratio of 0.84, a current ratio of 1.09 and a debt-to-equity ratio of 0.23. Astellas Pharma has a twelve month low of $9.11 and a twelve month high of $17.35. The company’s 50-day moving average price is $15.35 and its two-hundred day moving average price is $14.48.

Astellas Pharma (OTCMKTS:ALPMY) last released its quarterly earnings results on Monday, April 27th. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.14. The firm had revenue of $3.38 billion for the quarter, compared to analysts’ expectations of $3.28 billion. Astellas Pharma had a net margin of 13.66% and a return on equity of 24.19%. As a group, analysts expect that Astellas Pharma will post 1.29 EPS for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).